Head & Neck Cancers Articles | Page 3

Study Supports Active Surveillance for Some Thyroid Cancer Patients
Results from an analysis of 3D tumor volume measurements shows papillary thyroid cancers ≤1.5 cm grew slowly during a period of active surveillance, suggesting that surgery may not be necessary for all patients.
Cabozantinib Active as Salvage Therapy in Thyroid Cancer
Cabozantinib (Cabometyx) demonstrated durable activity in patients with radioiodine-refractory differentiated thyroid cancer who progressed on VEGFR-targeted therapy.
Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma
Pembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.
EBV DNA Screening Detects Early Asymptomatic Nasopharyngeal Carcinoma
Hong Kong researchers were able to detect nasopharyngeal carcinoma significantly earlier by screening for circulating cell-free Epstein-Barr virus DNA.
Novel Regimen May Eliminate Need for Radiation in Some Oropharyngeal Cancers
Robert Siegel, MD, discusses the 13-month follow-up of the combination of induction chemotherapy and transoral surgery in oropharyngeal squamous cell carcinoma.
Frontline Pembrolizumab Explored in Head and Neck Cancer
Jean-Pascal Machiels, MD, discusses the KEYNOTE-412 trial and the overall potential for pembrolizumab in the head and neck cancer landscape.
Expert Highlights Avelumab Trial and Future of Immunotherapy in Head and Neck Cancer
Nancy Y. Lee, MD, discusses the ongoing JAVELIN HEAD AND NECK 100 trial and the overall impact of immunotherapy for patients with head and neck cancer.
Erlotinib Linked to Improved Survival in HNSCC
Results showed that adding erlotinib to cisplatin and docetaxel was superior to chemotherapy alone for both overall survival and progression-free survival in head and neck squamous cell carcinoma.
FDA Accepts sBLAs for 4-week Nivolumab Dosing Schedule
The FDA has accepted supplemental Biologics License Applications seeking to add a second dosing schedule for nivolumab (Opdivo) across all of the PD-1 inhibitor’s monotherapy indications.
Pembrolizumab Falls Short in Phase III Head and Neck Cancer Trial
Pembrolizumab (Keytruda) did not meet the primary endpoint of overall survival in the phase III KEYNOTE-040 trial in patients with previously-treated recurrent or metastatic head and neck squamous cell carcinoma.
Publication Bottom Border
Border Publication